Dear Friends and Colleagues,

Following the great success of the 1st World Congress on Controversies in Hematology (COHEM) which attracted almost 500 participants from more than 60 countries, we are delighted to invite you to participate in the 2nd World Congress on Controversies in Hematology (COHEM) which will take place on September 6-8, 2012.

The 2nd COHEM Congress aims to circulate up to date information and to provide a unique opportunity for world leaders in the field to debate the most vital and contentious issues in benign and malignant Hematology. This thought-provoking academic dialogue will raise the most challenging current clinical and technological questions.

By allocating substantial time for discussions following each debate, audience members are encouraged to take a participating role in this influential academic dialogue. These exciting debates will highlight the key issues raised in 2011 and 2012 and provide clinicians with state-of-the-art recommendations regarding patient care.

We invite you to participate in the 2nd COHEM Congress and to take an active role in this innovative and interactive experience.

We look forward to welcoming you at this fascinating scientific event!

Prof. Robin Foà
Italy
Prof. Rüdiger Hehlmann
Germany
Prof. Emili Montserrat
Spain
Prof. Eliezer Rachmilewitz
Israel
Prof. Giuseppe Saglio
Italy
Co-Chairpersons

Prof. Charles Schiffer
USA

FACULTY

E. Angelucci, Italy
M. Baccarani, Italy
T. Barbui, Italy
B. Barlogie, USA
G. Barosi, Italy
M. Boccadoro, Italy
A.K. Burnett, UK
J. Bussel, USA
Y. Cabantchik, Israel
M.D. Cappellini, Italy
B. Coiffier, France
J. Connors, Canada
A. Engert, Germany
J. Esteve, Spain
A. Falanga, Italy
B. Falini, Italy
A. Piga, Italy
G. Rodger, UK
R. Foà, Italy
G. Saglio, Italy
G. Gaidano, Italy
A. Hagenbeek, The Netherlands
C. Haioun, France
R. Hehlmann, Germany
D. Hoelzer, Germany
E. Kimby, Sweden
N. Kröger, Germany
F. Lo-Coco, Italy
J.P. Marie, France
E. Montserrat, Spain
A. Nagler, Israel
E. Olavarria, Spain
A. Palumbo, Italy
E. Rachmilewitz, Israel
A.C. Rawstron, UK
J.M. Ribera, Spain
E. Rachmilewitz, Israel
A.C. Rawstron, UK
J.M. Ribera, Spain
G. Rodgers, USA
G. Saglio, Italy
G. Saglio, Italy
G. Saglio, Italy
M.M. Samama, France
J.F. San-Miguel, Spain
V. Santini, Italy
M.A. Sanz, Spain
C. Schiffer, USA
S. Sheth, USA
J. Sierra, Spain
R. Stasi, UK
J.L. Steegmann, Spain
S. Stilgenbauer, Germany
A. Tefferi, USA
W. Vainchenker, France
A. Vannucchi, Italy
U. Vitolo, Italy
J.L. Vives Corrons, Spain
J. Yahalom, USA
P.L. Zinzani, Italy

## THURSDAY, SEPTEMBER 6, 2012

### HALL A

**15:30-17:45**

**PLENARY SESSION 1**

**DEBATES IN APL, AML & CLL**

**Chairpersons opening remarks**

**Is there a possibility to cure APL without chemotherapy in the future?**

**Moderator:** G. Saglio, Italy

*Yes:* M.A. Sanz, Spain

*No:* F. Lo-Coco, Italy

**Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?**

**Moderator:** A.K. Burnett, UK

*Yes:* B. Falini, Italy

*No:* C. Schiffer, USA

### 17:45-18:15

**Coffee Break**

### 18:15-19:30

**SATELLITE SYMPOSIUM**

EMERGING STRATEGIES FOR RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA: ADDRESSING UNMET NEEDS

*Sponsored by ARIAD Pharmaceuticals, Inc.*

### 19:30-21:00

**Welcome Reception**

---

## FRIDAY, SEPTEMBER 7, 2012

### HALL A

**08:30-10:00**

**SESSION 2**

**AML**

Should patients with high risk MDS (and AML in early relapse) proceed directly to allogeneic transplantation without prior induction chemotherapy?

**Moderator:** M.A. Sanz, Spain

*Yes:* A.K. Burnett, UK

*No:* P. Fenaux, France

Should older patients with AML be considered for lower intensity approaches rather than 3 & 7?

**Moderator:** J. Esteve, Spain

*Yes:* J. Sierra, Spain

*No:* C. Schiffer, USA

### 10:00-10:30

**Coffee Break**

### 10:30-12:00

**SESSION 4**

**ALL**

Should “pediatric”-like strategies be extended over the age of 35?

**Moderator:** D. Hoelzer, Germany

*Yes:* J.M. Ribera, Spain

*No:* J.P. Marie, France

Can ALL be managed without chemotherapy/ transplant?

**Moderator:** C. Schiffer, USA

*Yes:* R. Foà, Italy

*No:* D. Hoelzer, Germany

### 12:00-13:00

**Lunch Break**

---

---
## PRELIMINARY SCIENTIFIC PROGRAM

### FRIDAY, SEPTEMBER 7, 2012

#### HALL B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td><strong>SESSION 3</strong> CLL</td>
<td>Moderator: R. Foà, Italy, Yes: E. Montserrat, Spain, No: A.C. Rawstron, UK</td>
</tr>
<tr>
<td></td>
<td>Monoclonal B-cell lymphocytosis: Much ado about nothing?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is the whole better than the sum of its parts? All “fit” older patients should receive FCR</td>
<td>Moderator: E. Montserrat, Spain, Yes: S. Stilgenbauer, Germany, No: R. Foà, Italy</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:30-12:00</td>
<td><strong>SESSION 5</strong> INDOLENT NON-HODGKIN LYMPHOMAS</td>
<td>Moderator: A. Hagenbeek, The Netherlands, Yes: U. Vitolo, Italy, No: E. Kimby, Sweden</td>
</tr>
<tr>
<td></td>
<td>Should all patients with follicular leukemia receive maintenance therapy?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituixa</td>
<td>Moderator: N. Kröger, Germany, Yes: B. Coiffier, France, No: A. Hagenbeek, The Netherlands</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Lunch Break</td>
<td></td>
</tr>
</tbody>
</table>

#### HALL B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15-15:45</td>
<td><strong>SESSION 7</strong> HODGKIN’S DISEASE</td>
<td>Moderator: P.L. Zinzani, Italy, Pro Chronos: J. Connors, Canada, Pro Kairos: TBA</td>
</tr>
<tr>
<td></td>
<td>Do we have one or two shots for cure in advanced Hodgkin’s disease? Kairos or Chronos?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Should therapy for HD be modified by the results of the early PET?</td>
<td>Moderator: TBA, Yes: P.L. Zinzani, Italy, No: A. Engert, Germany</td>
</tr>
<tr>
<td>15:45-16:15</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

### SATURDAY, SEPTEMBER 8, 2012

#### HALL A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td><strong>SESSION 10</strong> CML</td>
<td>Moderator: G. Saglio, Italy, Yes: R. Heilman, Germany, No: M. Bacarani, Italy</td>
</tr>
<tr>
<td></td>
<td>Are TKI sufficient for the treatment of CML, or should TKI be combined with other agents or treatment modalities?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Should patients treated with second line TKIs be considered for allo BMT?</td>
<td>Moderator: R. Heilman, Germany, Yes: E. Olayvaria, Spain, No: J.L. Steegmann, Spain</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

#### HALL A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-12:00</td>
<td><strong>SESSION 12</strong> HEMOGLOBINOPATHIES</td>
<td>Moderator: E. Rachmilewitz, Israel, Yes: E. Angelucci, Italy, No: M.D. Cappellini, Italy</td>
</tr>
<tr>
<td></td>
<td>Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is there a rationale for treatment of sickle cell anemia except for acute complications?</td>
<td>Moderator: G. Rodgers, USA, Yes: S. Sheth, USA, No: J.L. Vives Corrons, Spain</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Lunch Break</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 14
BIOMARKERS
Are the new molecular and cytogenetic markers useful for the management of MNP’s?
Moderator: A. Tefferi, USA
Yes: W. Vainchenker, France
No: G. Barosi, Italy

Is serum ferritin a sufficient marker for evaluation and monitoring treatment of iron overload?
Moderator: E. Rachmilewitz, Israel
Yes: A. Piga, Italy
No: Y. Cabantchik, Israel

SESSION 15
COAGULATION
What should be the next step after failure of steroids in ITP – splenectomy versus Rituximab or TPO mimetics?
Moderator: M.M. Samama, France
Splenectomy & Rituximab: R. Stasi, UK
TPO mimetics: J. Busel, USA

New anticoagulants: Monitoring or not Monitoring?
Moderator: J. Busel, USA
Monitoring: M.M. Samama, France
Not Monitoring: A. Falanga, Italy
GENERAL INFORMATION

VENUE
Princesa Sofia Hotel
Plaza Pius XII, 4
Barcelona 08028, Spain
Website: www.princesasofia.com

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>Early Registration until June 27, 2012</th>
<th>Late Registration from June 28 until August 27, 2012</th>
<th>From August 28, 2012 and on-site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants - Physicians and Scientists</td>
<td>€540</td>
<td>€590</td>
<td>€650</td>
</tr>
<tr>
<td>Residents, Nurses, Students</td>
<td>€385</td>
<td>€430</td>
<td>€470</td>
</tr>
</tbody>
</table>

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

ACCOMMODATION
ComtecMed is the official travel agent for the 2nd World Congress on Controversies in Hematology (COHEM) and is offering special reduced rates for the Congress participants.

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Category</th>
<th>Single Room</th>
<th>Double Room</th>
<th>Distance from Congress Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Princesa Sofia Hotel</td>
<td>5 Stars</td>
<td>€175</td>
<td>€190</td>
<td>Congress Headquarter Hotel</td>
</tr>
</tbody>
</table>

Rates quoted are per room, per night, including breakfast and VAT. Additional hotels in different categories are available upon request.

SPONSORS

GOLD
ARIAD
Takeda
Takeda Millenium

SILVER
Bristol-Myers Squibb
GSK

SPONSOR
IPSOGEN